IDXX - IDEXX Laboratories, Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $3.46
|
Rev Est: $1.1B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$784.38
DETAILS
HIGH:
$830.00
LOW:
$730.00
MEDIAN:
$792.50
CONSENSUS:
$784.38
UPSIDE:
20.82%
Market Cap:
51.84B
Volume:
790,711
Avg Volume:
519,133
52 Week Range:
356.14-769.98
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
1.66
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
11,000
IPO Date:
1991-06-21
EPS (TTM):
13.17
P/E Ratio:
51.15
Revenue (TTM):
4.30B
Total Assets:
3.35B
Total Debt:
1.08B
Cash & Equiv:
180.07M
Rev Growth (5Y):
9.7%
EPS Growth (5Y):
14.1%
FCF Growth (5Y):
14.3%
ROCE:
61.9%
Debt/Equity:
0.67
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-02 | $3.08 | $2.93 | +5.1% | $1.1B | $1.1B | +1.7% |
| 2025-11-03 | $3.40 | $3.14 | +8.3% | $1.1B | $1.1B | +3.0% |
| 2025-08-04 | $3.63 | $3.28 | +10.7% | $1.1B | $1.1B | +4.4% |
| 2025-05-01 | $2.96 | $2.85 | +3.9% | $998.4M | $997.1M | +0.1% |
| 2025-02-03 | $2.62 | $2.39 | +9.6% | $954.3M | $935.1M | +2.0% |
| 2024-10-31 | $2.80 | $2.68 | +4.5% | $975.5M | $980.3M | -0.5% |
| 2024-08-06 | $3.02 | $2.88 | +4.9% | $1.0B | $1.0B | -0.3% |
| 2024-05-01 | $2.81 | $2.67 | +5.2% | $964.1M | $964.4M | 0.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.30B | 3.90B | 3.66B | 3.37B | 3.22B | 2.71B | 2.41B | 2.21B | 1.97B | 1.78B | 1.60B | 1.49B |
| Net Income | 1.06B | 887.87M | 845.04M | 679.09M | 744.85M | 581.78M | 427.72M | 377.03M | 263.14M | 222.04M | 192.08M | 181.91M |
| EPS | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 | 4.34 | 3.00 | 2.47 | 2.07 | 1.82 |
| Total Assets | 3.35B | 3.29B | 3.26B | 2.75B | 2.44B | 2.29B | 1.83B | 1.54B | 1.71B | 1.53B | 1.47B | 1.38B |
| Total Debt | 1.08B | 986.95M | 1.07B | 1.47B | 1.03B | 1.00B | 1.07B | 1.00B | 1.26B | 1.20B | 1.17B | 899.00M |
| Cash & Equivalents | 180.07M | 288.27M | 453.93M | 112.55M | 144.45M | 383.93M | 90.33M | 123.79M | 187.68M | 154.90M | 128.99M | 322.54M |
| Operating Cash Flow | 1.18B | 929.00M | 906.51M | 542.98M | 755.55M | 648.06M | 459.16M | 400.08M | 373.28M | 334.57M | 216.36M | 235.85M |
| Free Cash Flow | 1.05B | 798.08M | 772.88M | 394.15M | 636.00M | 540.44M | 303.93M | 277.15M | 296.57M | 269.78M | 133.44M | 175.15M |
| FCF per Share | 13.15 | 9.68 | 9.30 | 4.71 | 7.46 | 6.33 | 3.53 | 3.19 | 3.38 | 3.01 | 1.44 | 1.75 |
| Book Value | 1.61B | 1.60B | 1.48B | 608.74M | 689.99M | 632.09M | 177.47M | (9.51M) | (54.11M) | (108.35M) | (84.12M) | 117.52M |
| Cash & ST Investments | 180.07M | 288.27M | 453.93M | 112.55M | 144.45M | 383.93M | 90.33M | 123.79M | 471.93M | 391.85M | 342.58M | 322.54M |
| ROC Equity | 0.66 | 0.56 | 0.57 | 1.12 | 1.08 | 0.92 | 2.41 | N/A | N/A | N/A | N/A | 1.55 |